Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Plus Chemotherapy vs Anti-PD-1 Plus Chemotherapy in Advanced Gastric/GEJ Cancer With Liver Metastases
NCT07677293Phase 3Not yet recruiting
- Sponsor
- Peking University
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of retlirafusp alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Peking University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07677293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677293.